Inovio Pharmaceuticals Reports Strong Financial Results and Exciting Updates on Pipeline Progress for 2023
Thursday, 7 March 2024, 04:30
Highlights:
- Inovio Pharmaceuticals: Strong financial results and advances in DNA medicines platform
- INO-3107 BLA Submission: Planned for second half of 2024 as potential non-surgical treatment for RRP patients
- Key Updates: Positive trial data, strategic partnerships, and planned launches in 2025
In 2023, Inovio Pharmaceuticals focused on advancing late-stage assets like INO-3107 and INO-3112. The company plans to submit a BLA for INO-3107 in the second half of 2024, aiming to offer a non-surgical treatment option for RRP patients. Strategic collaborations, positive trial results, and preparations for potential launches in 2025 demonstrate promising developments in the pipeline.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.